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Articular cartilage (AC) injury is a common disorder. Numerous techniques have been employed to repair or regenerate the
cartilage defects with varying degrees of success. Three commonly performed techniques include bone marrow stimulation,
cartilage repair, and cartilage regeneration. This paper focuses on current level of evidence paying particular attention to cartilage
regeneration techniques.
1.Introduction
AC injury is a common disorder of the knee. It aﬀects people
of all ages and sexes. With the ever-increasing population
and the active lifestyle of the older generation, incidence of
AC injuries is on the rise. In the USA more than 500,000
procedures are performed for cartilage-related injuries and
majority represent repeat procedures suggesting an ineﬀec-
tiveness of surgical treatment [1]. The incidence of cartilage
defects has been reported to be as high as 65% in routine
knee arthroscopies [2–5]; however, the relevance of these
defects to symptomatology is not yet clear. Hunter reported
the inability of articular cartilage to regenerate in 1743 [6].
Early chondral lesions are often not detected due to lack of
nerve supply, and the absence of vascularity limits the repair
potential.
AC integrity is important for various reasons. Firstly,
chondral lesions may cause mechanical symptoms such as
swelling and pain. Secondly the progression to osteoarthritis
is accelerated as reported by Mankin and Davis [7, 8]. Sahl-
storm has reported radiographic evidence of OA in 100%
patients in Ahlbeck stage II and III lesions at 20 years [9].
And thirdly the complexity of its structure and functional
properties such as minimizing friction and increasing con-
tact surface area to decrease wear under load bearing makes
it a diﬃcult material to repair.
ACworksnotonlytoprotecttheunderlyingsubchondral
bonebutalsoservestominimizefrictionandmaximizeload-
bearing articular surface. Thus treatment of AC loss aims
to restore these properties. AC is composed of chondro-
cytes (5–10%), water (65–80%), collagen, large negatively
charged hydrophilic proteoglycans (aggrecan, hyaluronan),
and smaller glycoproteins such as ﬁbronectin and cartilage
oligomericproteins[10].Microscopically,fromsuperﬁcialto
deep, fourdistinct zones of AC are described [11].The super-
ﬁcial zone is composed mainly of elongated chondrocytes.
The smaller diameter collagen ﬁbers (mainly type II) run
parallel to the articular surface in this layer. The transitional
zone is composed of large-diameter collagen ﬁbers. The deep
zone has perpendicularly arranged collages ﬁbers and high
proteoglycan content, and ﬁnally there is the calciﬁed carti-
lage zone. Type II collagen is the predominant form (95%)
but types VI, IX, X, and XI are also found (mostly in the
calciﬁed layer). As the chondrocytes move closer to the sup-
erﬁcial zone, they become ﬂatter in a ﬁbroblastic shape. Such
an arrangement of cells along with the collagen network in
the superﬁcial zone gives hyaline cartilage its resistance to
shearforces,whereasinthesuperﬁcialzoneproteinlubricant
secreted by the chondrocytes reduces the coeﬃcient of fri-
ction.
AC injury may be chondral or osteochondral if involving
the underlying bone. The insult to AC can be traumatic2 Advances in Orthopedics
or degenerative. Various metabolic factors such as obesity,
alcohol abuse, and diabetes as well as mechanical factors like
instability, trauma, and joint misalignment are implicated
in its etiology. [12]. Pure chondral injures are painless and
repair poorly due to lack of vascularity. Osteochondral in-
jures heal by ﬁbrocartilage secondary to initial inﬂammatory
response. Although mesenchymal cells produce type I and II
collagen, repair is mostly ﬁbrocartilagenous in nature. It
lacks the orderly structural organization of the normal hya-
line cartilage and results in early degradation and fragmen-
tation [13].
Both nonoperative and operative techniques have been
employed in treating AC defects. The primary aim of any
treatment modality is to reduce pain and restore func-
tion. Nonoperative treatments include weight loss, mus-
cle strengthening physiotherapy, viscosupplementation with
hyaluronic preparations, steroid injections, and oral chon-
droitin sulphate [14–17]. Operative treatment is broadly
classiﬁed in three categories, namely, bone marrow stimula-
tion (BMS) techniques, cartilage replacement techniques, and
cartilage regeneration techniques. This paper aims to review
thecurrentconceptsinthemanagementofarticularcartilage
defectsinthekneejointwithparticularemphasisoncartilage
regeneration techniques.
2. Bone Marrow Stimulation (BMS) Techniques
2.1. Drilling/Microfracture/Abrasion Techniques. BMS tech-
niques aim to stimulate the migration of mesenchymal stem
cells to subchondral bone. Microfracture technique was ﬁrst
described by Steadman [18]. The scientiﬁc basis of this
technique is to recruit the mesenchymal stem cells from
to the surface of bleeding bone. They secrete ﬁbrocartilage
which is mainly composed of type I collagen. Such a repair
tissue may be able to ﬁll in the defect, but lacks the normal
histological or biomechanical properties of hyaline cartilage.
Therefore, it has inferior stability to compressive and shear
forces and tends to deteriorate with time [19]. Younger
age has been associated with better outcome. In a series
of 72 patients younger than 45, Steadman has reported an
improved outcome in 80% patients at 7 years [19]. Kreutz
et al. have also shown better radiological ﬁll of the cartilage
defects with higher Cincinnati knee scores and ICRS in
patients younger than 40 [20]. Decline in clinical outcome
after 18–36 months is also more pronounced in older age
individuals [20]. Comparison of BMS technique with repair
or regenerative techniques is discussed further in the next
sections.
3. CartilageReplacement Techniques
3.1. Chondrocyte Autograft Transfer and Mosaicplasty. Two
techniques described for cartilage replacement are Chondro-
cyte autograft transfer (OAT) and Mosaicplasty. OAT has
been in practice since 1990s [21]. Osteochondral plugs are
harvested from non-weight-bearing surface of the ipsilateral
jointandplacedinthepreparedcylindricalholeintheregion
of cartilage defect. The limiting factor of size in OAT led to
development of mosaicplasty, which harvests multiple small
osteochondral plugs. Due to multiple cone implantations,
the gaps between the plugs produce an uneven joint surface
[22]. Microfracturing the gaps and insertion of Osteogenic
Protein (BMP-7) have been used with varying results [23].
Due to the technical diﬃculties and donor site morbidity
of mosaicplasty, its use is infrequent. However, a trend has
been observed in single osteochondral grafts in isolated
cartilage defects [24]. In a series of over 900 osteochondral
grafts of the knee over a period of 15 years, Hangody et al.
have reported good to very good results in 92% patients with
femoral defects, 87% in tibia and 74% in patellofemoral
joints [25]. Other authors have also reported 84 to 88% good
to very good results at 2–4-year followup [26, 27]. When
compared to Autologous Chondrocyte Implantation (ACI),
Bentley has shown good to excellent results in 88% of pa-
tients with ACI compared to 69% following mosaicplasty
[28]. On the other hand, Horas et al. have shown better
clinical and histological outcome with mosaicplasty [29].
Complications of the osteochondral grafting include do-
nor site morbidity with a 2.3% risk of patellofemoral arthri-
tis [25]. Unsatisfactory ﬁlling of the cartilage defect (espe-
cially with grafts >8mm in diameter) and ﬁbrocartilage hy-
pertrophyofthe donor site havealsobeendescribed [27,30].
4. CartilageRegeneration Techniques
4.1. Autologous Chondrocyte Implantation (ACI). The most
widely practiced cartilage regeneration technique is autol-
ogous chondrocyte implantation (ACI), which was ﬁrst
described by Brittberg in 1994 [31]. Since then ACI has
gained widespread popularity. ACI involves harvesting the
normal cartilage from a non-weight-bearing aspect of the
ipsilateraljoint.Thechondrocytesarethenexpandedinvitro
and subsequently implanted in the chondral defect. The
main purpose of ACI is to implant chondrocytes in cartilage
defect so that a hyaline cartilage is produced which closely
resembles the normal AC in structural organization and
functional characteristics. ACI is ideally used in femoral con-
dylar AC defects, as results from patellar and tibial lesions
are inconsistent. ACI is preferredin youngerpatients with no
concomitant ligamentous instability and meniscal tears. Ad-
ditionalproceduresincludingmeniscectomyorligamentsta-
bilization may be necessary to achieve optimum outcome. A
rigorous postoperative rehabilitation regime is also followed
for maximum beneﬁt. Contraindications to ACI include his-
tory of septic arthritis and inﬂammatory arthritis such as
rheumatoid.
5.SurgicalTechnique
ACI is a two-staged procedure. An initial arthroscopy is per-
formed to evaluate the lesion. 3 to 4 chondral biopsies of
AC are taken from non-weight-bearing surfaces of the joint
(intercondylar notch, peripheral edges of femoral condyles).
The specimen is then transported to the laboratory where
the chondrocytes are isolated with an enzymatic process.
The chondrocytes are then cultured for 3 to 4 weeks until
volume increases by 30-fold for implantation (12 million
chondrocytes approx.). Usually at 6 weeks from the initialAdvances in Orthopedics 3
surgery a second stage operation is carried out. Depending
upon the location of the lesion, a medial or lateral patel-
lar arthrotomy is performed. The defect is debrided and
fashioned. A periosteal ﬂap is then harvested from proximal
tibia (medial femoral condyle can also be used). The ﬂap is
then secured to the defect (with its cambium layer facing the
bone) on all sides except superiorly. The cultured chondro-
cytes are then injected under the ﬂap and ﬁnally the ﬂap is
then attached superiorly as well. Fibrin glue may be used to
seal the edges of the ﬂap.
Postoperative rehabilitation involves early range of mo-
tion with protective weight bearing in a knee brace. Full
weight bearing is usually achieved at 8 weeks. Subsequently
light resistance and balance training is started. After 3 to 4
monthsstrengthgainingexercisesarestartedandmostphysi-
cians allow their patients to resume light athletic activities at
6 months. Return to full impact contact sport is usually not
recommended until 12–18 months after-procedure.
6. IsACI Effective?
Success of cartilage regeneration is based on its clinical, ra-
diological, and histological outcome. In a number of obser-
vational studies, good to excellent clinical results have been
obtained at short-to-medium-term followup [31–33]. When
comparing ACI to OATS, Horas showed similar outcomes
with both procedures; however, the speed of recovery was
slower with ACI [29]. Bentley showed good to excellent re-
sults in 89% patients following ACI compared to 69% fol-
lowing mosaicplasty [28]. Dozin, on the other hand, ob-
served improvement in 88% patients after mosaicplasty
versus only 68% in ACI group [34]. Saris compared chon-
drocyte implantation with microfracture technique and
found better cartilage histomorphometry at 12 months after
chondrocyte implantation; however, no diﬀerence was
observed in clinical outcome (KIIS, Knee Injury and Osteo-
arthritis Outcome score) at 12–18 months [35]. In another
randomized controlled trial (RCT), Knutsen found no dif-
ferenceinclinicalandradiologicaloutcomebetweenACIand
microfracturetechnique[36].ComparingclassicalACIusing
a periosteal ﬂap with newer generation type I/III collagen
membranes, Gooding et al. observed no diﬀerence in func-
tional outcome at two years [37]. A similar RCT comparing
ACI with matrix-induced ACI by Bartlett et al. also found no
signiﬁcant diﬀerence between the two techniques [38].
The drawbacks of ACI procedure include graft hypertro-
phy, which may need debridement (36% incidence). It in-
volves two surgical procedures and is expensive to culture
the chondrocytes in vitro. Due to the technical challenges of
ACI procedure as well as the need for bigger surgical ex-
posure, the need for an easier and eﬀective method of in-
jecting the chondrocytes into the joint has been long felt [38,
39]. This has led to the evolution of classical ACI into 2nd-
and 3rd-generation procedures. 2nd-generation ACI used
cultured chondrocytes but replaced the periosteal ﬂap with a
resorbable collagen matrix. In the 3rd-generation technique
chondrocytesareseededontoatypeI/IIIcollagenmembrane
and are then suspended into the defect site with ﬁbrin glue.
Amongst various commercially available membranes, the
most commonly performed procedure is called matrix-in-
duced autologous chondrocyte implantation (MACI, Gen-
zymeBiosurgery,Cambridge,MA,USA).MACInotonlyhas
the advantages of reduced operating time [40]a n dr e d u c e d
tourniquet time, it has also shown similar clinical results as
traditional ACI.
The principle of MACI technique is to culture the chon-
drocytes onto a biocompatible three-dimensional scaﬀold
(puriﬁed and cell free porcine collagen), which then would
be implanted into the cartilage defect [41]. MACI still
requires harvesting of chondrocytes from the native joint.
The overall procedure is same as 1st-generation ACI except
that instead of a periosteal ﬂap, a three-dimensional scaﬀold
of type I/III collagen is used. The scaﬀold is preseeded with
chondrocytes. Cells grown on cartilage scaﬀold are capable
of synthesizing chondrocyte matrix components such as
chondroitin sulphate and glycosaminoglycans as well as S-
100 protein (a cytoplasmic marker ofchondrocytes) [42,43].
The scaﬀold-chondrocyte complex is then directly applied
to the AC defect after debridement and adhered with ﬁbrin
glue. A suture is sometimes necessary in large uncontained
defects to secure the ﬁxation. As extended dissection is not
needed for harvesting a periosteal ﬂap, this procedure can be
doneviaminiarthrotomyorarthroscopy.Afterapplicationof
ﬁbrin glue, pressure is applied for several minutes to obtain
maximum adherence. The advantage of this technique is the
shorter duration and that it can be performed at the same
t i m eo fo t h e rp r o c e d u r e ss u c ha sA C Lr e c o n s t r u c t i o n ,h i g h
tibial osteotomy, and bone grafting [40].
Postoperatively, the joint is immobilized in extension.
At 10 days, a supervised rehabilitation program is started.
Continuous passive motion (CPM) has been shown to stim-
ulate glycosaminoglycans, type II collagen, and chondroitin
sulphatesynthesis[44].Aprotectedweight-bearingregimeis
usually followed for eight to twelve weeks. The patient is not
allowed to return to full sporting activities for approximately
18 months. Early accelerated rehabilitation (eight weeks) has
shown no negative eﬀect compared to delayed rehabilitation
(eleven weeks) at short-term followup (3 months) [45]. Re-
centlyevidencehasshownbetterclinicaloutcomewithaccel-
erated rehabilitation including early weight bearing and ra-
nge of movement exercises [46–48].
7. Is MACI Superiorto Other Cartilage
Regeneration Techniques?
MACI is a newer technique and data regarding its eﬃcacy is
at best scarce. Several case series have described its eﬃcacy
and good short-term results; however, the long-term follow-
up is lacking. Behrens, Elbert, Ventura, and Schneider et al.
have described signiﬁcant improvement in International
Knee Documentation Committee (IKDC) Tegner Activity
Score and Lysholm and Gillquist scores [46, 49–51]. How-
ever, randomised trials by Bartlett, Zeifang, and Manfredini
comparing the outcome following MACI versus standard
ACI using periosteal ﬂap failed to show superiority of the
MACI technique [38, 52, 53]. Zeifang et al. noted no dif-
ference in IKDC, Tegner Activity Score, and Short Form-36
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with ACI technique on Lysholm and Gillquist scoring [52].
Bartlett et al. also observed no diﬀerence in the outcome fol-
lowing the two procedures [38]. Graft hypertrophy has been
reported at almost 25% in MACI; however, it has not been
associated with worse clinical outcome [54]. New experim-
entalstudieshavebeencarriedoutinsheepmodelstoreplace
the articular chondrocytes with prediﬀerentiated mesenchy-
mal stem cells. Initial results have shown good histological
repair with less degradation at 1 year compared to classical
articular chondrocyte [55] .T h i s ,i fp r o v e ds u c c e s s f u li nh u -
mans, may substitute the need for the primary procedure to
harvest the chondrocytes.
8. Conclusion
In conclusion, the search for ideal cartilage repair technique
continues. The newer generation repair techniques have
shown some promise, but long-term outcome is still un-
known. Genetic modulation of mesenchymal stem cells and
chondrocytes with viral and nonviral vectors has also shown
potential but needs further evaluation. Long-term data is
required to prove the real beneﬁt of these costly interven-
tions. While MACI has shown good early results, its long-
term eﬃcacy is unknown. Microfracture and abrasion ar-
throplasty are cheap and easier to do but do not provide a
durable repair. OAT and mosaicplasty are extremely tech-
nically demanding with variable outcomes. Therefore arti-
cularcartilagerepairremainsunderintenseinvestigationand
a ni d e a lc u r ei sy e tt ob ed e ﬁ n e d .
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